Microscopic polyangiitis medical therapy: Difference between revisions
| Line 17: | Line 17: | ||
* If Microscopic polyangiitis is severe, plasmapheresis may also be given in conjunction with an immunosuppressant and glucocorticoid. | * If Microscopic polyangiitis is severe, plasmapheresis may also be given in conjunction with an immunosuppressant and glucocorticoid. | ||
* Plasmapheresis has been shown to have benefit in patients with pulmonary and renal involvement. | * Plasmapheresis has been shown to have benefit in patients with pulmonary and renal involvement. | ||
** Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days | |||
=== '''Rituximab''' === | === '''Rituximab''' === | ||
* Induction therapy using rituximab and glucocorticoids in a recent study conducted by RITUXVAS compared rituximab and cyclophosphamide. | * Induction therapy using rituximab and glucocorticoids in a recent study conducted by RITUXVAS compared rituximab and cyclophosphamide.<ref name="pmid18281850">{{cite journal |vauthors=Jayne D |title=Challenges in the management of microscopic polyangiitis: past, present and future |journal=Curr Opin Rheumatol |volume=20 |issue=1 |pages=3–9 |date=January 2008 |pmid=18281850 |doi=10.1097/BOR.0b013e3282f370d1 |url=}}</ref> | ||
* The trial showed no superiority, in that both medications were effective at inducing remission. However, the safety and the long term use of rituximab needs to be further addressed. | * The trial showed no superiority, in that both medications were effective at inducing remission. However, the safety and the long term use of rituximab needs to be further addressed. | ||
Revision as of 16:14, 26 April 2018
|
Microscopic polyangiitis Microchapters |
|
Differentiating Microscopic polyangiitis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Microscopic polyangiitis medical therapy On the Web |
|
American Roentgen Ray Society Images of Microscopic polyangiitis medical therapy |
|
Risk calculators and risk factors for Microscopic polyangiitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]
Overview
Microscopic polyangiitis responds well to treatment with glucocorticoids such as prednisone together with a immunosuppressant such as cyclophosphamide. The combination of these 2 drugs decreases the remission of Microscopic polyangiitis by about 90%.
Medical Therapy
- Pharmacologic medical therapies for Microscopic polyangiitis include glucocorticoids and immunosuppressant.[1]
Corticosteroids:
- In more aggressive forms of the disease prednisone is interchanged with methylprednisolone which is given intravenously at a dose of 1 g/kg 3 times a day.
- Both mild and severe forms of the disease are administered together with cyclophosphamide which is given in intravenous pulses every 2 weeks at a dose of 15 mg/kg for the first three infusions.
- After the first 3 doses, cyclophosphamide is administered every 3 weeks at 15 mg/kg.
- Cyclophosphamide can also be given orally at a dose of 2 mg/kg/day, however, more side effects are seen with the oral dose, such as neutropenia.
- The dose of prednisone that is given is 1 mg/kg/day for less aggressive forms of the disease
- If Microscopic polyangiitis is severe, plasmapheresis may also be given in conjunction with an immunosuppressant and glucocorticoid.
- Plasmapheresis has been shown to have benefit in patients with pulmonary and renal involvement.
- Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days
Rituximab
- Induction therapy using rituximab and glucocorticoids in a recent study conducted by RITUXVAS compared rituximab and cyclophosphamide.[2]
- The trial showed no superiority, in that both medications were effective at inducing remission. However, the safety and the long term use of rituximab needs to be further addressed.
Maintenance Therapy
The maintenance therapy for Microscopic polyangiitis is with azathioprine, which is less toxic to that of cyclophosphamide. Azathioprine is administered for 18 months at a dose of 1 to 2 mg/kg/day.
Other medications that may be used as maintenance are:
- Myclophenolate mofetil: up to 1g twice a day
- Methotrexate: 0.3 to 25 mg/kg/week
References
- ↑ Greco A, De Virgilio A, Rizzo MI, Gallo A, Magliulo G, Fusconi M; et al. (2015). "Microscopic polyangiitis: Advances in diagnostic and therapeutic approaches". Autoimmun Rev. 14 (9): 837–44. doi:10.1016/j.autrev.2015.05.005. PMID 25992801.
- ↑ Jayne D (January 2008). "Challenges in the management of microscopic polyangiitis: past, present and future". Curr Opin Rheumatol. 20 (1): 3–9. doi:10.1097/BOR.0b013e3282f370d1. PMID 18281850.